InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,522.30
(
1.58%
)
US TECH 100
18,951.20
(
0.58%
)
Dow Jones
40,842.79
(
0.00%
)
Brent Oil
81.38
(
-0.17%
)
Bitcoin
64,496.49
(
-0.16%
)
Post# of 252758
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: genisi post# 121754

Thursday, 06/16/2011 8:41:25 PM

Thursday, June 16, 2011 8:41:25 PM

Post# of 252758

Based on this data and the overall clinical profile of CXA-201, the company will be engaging global regulatory authorities to discuss a CXA-201 nosocomial pneumonia Phase 3 study design and expects to begin Phase 3 studies in this indication in 2012.



It's interesting CBST is committed to start phase III for CXA201, but not CB-183,315.

From Biocentury:

Cubist plans to announce a formal decision on whether to start Phase III testing with CB-183,315 by year end.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up